Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics (PSTV)
:PSTV
PSTV Stock Chart & Stats
$0.58
-$0.05(-4.03%)
At close: 4:00 PM EST
$0.58
-$0.05(-4.03%)
Day’s Range― - ―
52-Week Range$0.16 - $2.31
Previous CloseN/A
Volume69.06K
Average Volume (3M)5.39M
Market Cap
$93.97M
Enterprise Value$56.87M
Total Cash (Recent Filing)$13.29M
Total Debt (Recent Filing)$21.00K
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Feb 19, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding137,429,060
10 Day Avg. Volume5,559,623
30 Day Avg. Volume5,388,962
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.85
Price to Sales (P/S)1.31
P/FCF Ratio-0.71
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue10.82
Enterprise Value/Gross Profit12.17
Enterprise Value/Ebitda-3.52
Forecast
1Y Price Target
$8.00Price Target Upside1279.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$4.27M
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsPlus Therapeutics is progressing well in its drug development with key milestones and data points expected.
Commercial Coverage ExpansionA major National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide has been announced, enhancing its market potential.
Financial StabilityPlus Therapeutics had $17 million in cash and no debt, which is believed to be enough to fund operations into Q4 2026.
Bears Say
Price Target AdjustmentThe 12-month price target has been lowered from $21 to $19, reflecting high clinical trial risks despite large market opportunities.
Regulatory ChallengesCNSide has only been launched in Texas, which may slow down revenue growth as the company navigates licensing and regulatory requirements in other states.
Valuation RisksPotential risks to the valuation of PSTV include clinical, commercial, partnership, financial, and intellectual property challenges.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $0.16 and its highest was $2.31 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $93.97M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 66 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Oct 30, 2025. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.02.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 137,429,060 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went up 1.887%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Plus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (1279.31% Upside)
$8.00 (1279.31% Upside)
Blogger Sentiment
Bullish
PSTV Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $52.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
167.56%
Trailing 12-Months
Company Description
Plus Therapeutics
Plus Therapeutics, Inc. (PSTV) is a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases. The company specializes in the development of targeted radiotherapeutics, which leverage the power of radiation to treat tumors while minimizing damage to surrounding healthy tissue. Plus Therapeutics is engaged in advancing its lead product candidates through clinical trials aimed at addressing unmet medical needs in oncology, particularly in the treatment of brain tumors and other solid tumors.
PSTV Stock 12 Month Forecast
Average Price Target
$8.00
▲(1279.31% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
0.35% Insiders
0.09% Mutual Funds
0.80% Other Institutional Investors
98.06% Public Companies and Individual Investors
Options Prices
Currently, No data available
---